Every Form 4 that Allogene Therapeutics, Inc. (ALLO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALLO filings page.
Allogene Therapeutics, Inc. (ALLO) reported that officer Douglas Earl Martin, SVP and General Counsel, sold 29,697 shares of common stock on August 21, 2026 at $2.12 per share. The shares were sold to cover tax withholding on vesting RSUs under a mandated "sell to cover" arrangement, so the trade was not discretionary. After this and related adjustments, including forfeiture of performance RSUs and prior ESPP purchases, he directly holds 488,267 shares of Allogene common stock.
Allogene Therapeutics President and CEO Zachary Roberts reported equity awards rather than open-market trades. He received a grant of 476,190 stock options to buy common stock at an exercise price of $2.11 per share, expiring on July 1, 2036. Twenty-five percent of these options vest on July 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
Roberts was also granted 134,530 Restricted Stock Units, each representing one share of common stock. These RSUs vest in four equal annual installments over the four-year period starting July 20, 2026, subject to his continued service. The filing shows compensation-related acquisitions, with no reported stock purchases or sales in the market.
Allogene Therapeutics director Joshua A. Kazam reported equity compensation activity. On June 18, 2026, he exercised 47,700 Restricted Stock Units (RSUs), which converted into the same number of common shares, bringing his direct common stock holdings to 398,463 shares after the transactions.
On the same date he received a new award of 95,400 RSUs under the company’s 2018 plan. Each RSU represents a contingent right to receive one share of Allogene common stock, or cash at the company’s discretion, and will vest in two equal semi-annual installments over one year, subject to continued service.
MESSEMER DEBORAH M. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Deborah M. Messemer received a grant of 95,400 restricted stock units (RSUs). The award carries no purchase price and gives her the contingent right to receive 95,400 shares of Allogene common stock if the units vest.
According to the terms, the RSUs will vest in two equal semi-annual installments over a one-year period from the grant date, subject to her continued service through each vesting date. Following this grant, she holds 95,400 RSUs directly.
Allogene Therapeutics director Stephen Mayo received a new stock option grant covering 144,400 shares of common stock. The options have an exercise price of $2.00 per share and vest in 12 equal monthly installments. Following this award, he holds options for 144,400 shares, expiring on June 18, 2036.
Allogene Therapeutics director Vicki L. Sato received a grant of 95,400 Restricted Stock Units. These RSUs give her the right to receive an equal number of Allogene common shares at future vesting dates, without paying an exercise price.
The award will vest in two equal semi-annual installments over one year from the grant date, as long as she continues to provide service through each vesting date. This filing does not report any open-market purchases or sales, only a compensation-related equity grant.
WITTE OWEN N. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Owen N. Witte received a grant of 95,400 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Allogene common stock. The RSUs vest in two equal semi-annual installments over one year from the grant date.
Witte has elected to defer receipt of the underlying common shares until the earlier of 30 days after his separation from continuous service with the company or a change in control of Allogene, in line with the company’s Non-Employee Director Compensation Policy.
Humer Franz B reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Franz B. Humer received an equity grant of 95,400 restricted stock units. Each RSU represents a contingent right to one share of Allogene common stock. The RSUs vest in two equal semi-annual installments over one year from the grant date, subject to continued service.
The director has elected to defer receiving the common shares until the earlier of 30 days after leaving continuous service with the company or a change in control of Allogene.
Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics, Inc. director Elizabeth A. Barrett received a grant of 95,400 Restricted Stock Units. Each RSU represents a contingent right to one share of Allogene common stock.
The RSUs vest in two equal semi-annual installments over one year from the grant date, subject to her continued service. Barrett has elected to defer delivery of the underlying shares until the earlier of 30 days after leaving continuous service or a change in control of the company.
Allogene Therapeutics SVP of Finance Annie Yoshiyama reported a small share sale mainly for tax purposes. She sold 9,586 shares of common stock in an open-market transaction to cover tax withholding obligations tied to the vesting of restricted stock units under a mandated “sell to cover” arrangement, rather than a discretionary trade. The weighted average sale price ranged from $2.31 to $2.33 per share. After this transaction, she directly holds 124,517 Allogene shares, which include 3,781 shares acquired on March 15, 2026 through an employee stock purchase program.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported a small sale of 2,867 shares of Common Stock at $2.50 per share. The company states this transaction was executed solely to cover tax withholding obligations tied to vesting restricted stock units under its equity incentive plan.
Following the sale, Beneski directly holds 195,338 shares of Allogene Therapeutics common stock. The filing explains the sale was a mandatory “sell to cover” transaction chosen by the company’s plan and is not a discretionary trade by the executive.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Beneski reported a small open-market sale of 4,835 shares of Common Stock at a weighted average price of $2.47 per share. The shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plan and were required by a “sell to cover” election, meaning the transaction was not a discretionary trade. After this sale, Beneski directly holds 198,205 shares of Allogene common stock.
Allogene Therapeutics President and CEO David D. Chang reported an open‑market sale of 47,763 shares of common stock at $2.47 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units, under a mandatory “sell to cover” feature of the company’s equity incentive plan, so this was not a discretionary trade. After the transaction, Chang directly holds 5,150,599 common shares, and additional shares are held indirectly through the RTC 2019 Trust, JEC 2019 Trust, and the Chang 2006 Family Trust.
Allogene Therapeutics, Inc. senior vice president and chief technical officer Benjamin Machinas Beneski reported a mandatory sale of common stock to cover taxes on vested restricted stock units. He sold 7,132 shares in a sell-to-cover transaction at a weighted average price of $2.60 per share, with individual sale prices ranging from $2.60 to $2.67. After this tax-related sale, he directly owned 203,040 shares of Allogene common stock. The filing notes this transaction was required under the company’s equity incentive plan and did not represent a discretionary trade by the executive.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported new equity awards and a small share sale. On February 2, 2026, he sold 7,549 shares of common stock at a weighted average price of $1.73 solely to cover tax withholding on vesting restricted stock units, under a mandatory “sell to cover” arrangement rather than a discretionary trade. He received a stock option for 373,757 shares at $1.87 per share, vesting 25% on February 2, 2027 and the balance in 36 monthly installments. He was also granted 105,720 restricted stock units, each representing one share, vesting in four equal annual installments starting February 2, 2026, subject to continued service. Following these transactions, he directly owned 210,172 shares of common stock.
Allogene Therapeutics President and CEO David D. Chang reported new equity awards and a tax-related share sale. On February 2, 2026, he received a stock option for 1,387,931 shares of common stock at an exercise price of $1.87 per share, vesting 25% on February 2, 2027, with the rest vesting in 36 equal monthly installments. He also received 392,586 restricted stock units, each representing one share of common stock, vesting in four equal annual installments from February 2, 2026, subject to continued service. To cover tax withholding on RSU vesting, 95,269 shares of common stock were sold at a weighted average price of $1.80 in a mandated "sell to cover" transaction, which the filing states was not a discretionary trade. After these transactions, he directly beneficially owned 5,185,862 shares of common stock and additional indirect holdings through several family trusts.
Allogene Therapeutics’ chief financial officer Geoffrey M. Parker reported routine equity compensation activity and a tax-related share sale. On February 2, 2026, he sold 24,001 shares of common stock at a weighted average price of $1.76 solely to cover tax withholding on vesting restricted stock units, under a mandated “sell to cover” arrangement. Following this, he directly owned 1,252,795 common shares. On the same date, he received a stock option to buy 539,072 shares at an exercise price of $1.87 per share, vesting 25% on February 2, 2027 and the rest in 36 monthly installments. He also received 152,480 restricted stock units, each equal to one share of common stock, vesting in four equal annual installments starting February 2, 2026, subject to continued service.
Allogene Therapeutics SVP and General Counsel Douglas Earl Martin reported new equity awards and a related share sale. On February 2, 2026, he was granted a stock option covering 539,072 shares of common stock at an exercise price of $1.87 per share. Twenty‑five percent of this option will vest on February 2, 2027, with the remaining shares vesting in 36 equal monthly installments.
He also received 152,480 restricted stock units, each representing one share of common stock, which will vest in four equal annual installments starting February 2, 2026, subject to continued service. On the same date, he sold 22,900 shares of common stock at a weighted average price of $1.76 to cover tax withholding obligations from RSU vesting, and this was not a discretionary trade. After the sale, he directly beneficially owned 564,948 shares of common stock.
Allogene Therapeutics, Inc. SVP Finance Annie Yoshiyama reported new equity awards and a small tax-related share sale. On February 2, 2026, she received a stock option for 179,691 shares of common stock at an exercise price of $1.87 per share and an award of 50,827 restricted stock units (RSUs). The option vests 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments, while the RSUs vest in four equal annual installments starting from February 2, 2026, subject to continued service. On the same date, she sold 4,167 shares of common stock at a weighted average price of $1.72 solely to cover tax withholding on vesting RSUs, under a mandatory “sell to cover” arrangement, and reported owning 130,322 common shares directly afterward.
Allogene Therapeutics EVP of R&D Zachary Roberts reported equity award grants and a tax-related share sale. On February 2, 2026, he was granted a stock option for 718,763 shares of common stock at an exercise price of $1.87 per share, vesting 25% on February 2, 2027 and the rest in 36 monthly installments. He also received 203,307 restricted stock units, which vest in four equal annual installments starting February 2, 2026, each RSU representing one share. The filing shows a sale of 35,700 common shares at a weighted average price of $1.77 solely to cover tax withholding on RSU vesting under a mandatory “sell to cover” arrangement, leaving him with 581,166 common shares held directly.
Allogene Therapeutics director Arie Belldegrun reported new equity awards and updated share holdings. On February 2, 2026, he was granted a stock option for 929,913 shares of common stock at an exercise price of $1.87 per share and an award of 263,033 restricted stock units (RSUs), both held directly.
Twenty-five percent of the option vests on February 2, 2027, with the balance vesting in 36 equal monthly installments. The RSUs vest in four equal annual installments starting February 2, 2026, subject to continued service. Indirect common stock holdings are reported in entities including Bellco Legacy Trust fbo Rebecka Belldegrun, Vida Ventures LLC, Vida Ventures III partnerships, and Bellco Legacy LLC, along with 2,236,816 common shares held directly.
Allogene Therapeutics, Inc. reported an insider transaction by EVP of R&D Zachary RobertsJanuary 21, 2026, Roberts sold 26,269 shares of Allogene common stock at $1.56 per share. According to the filing, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, under a mandated “sell to cover” election in the company’s equity incentive plan, and are not a discretionary trade by Roberts.
Following this transaction, Roberts beneficially owned 616,866 shares of Allogene common stock in direct ownership.
Allogene Therapeutics (ALLO) reported an insider transaction by its SVP and Chief Technical Officer on a Form 4. On 11/17/2025, the executive sold 786 shares of common stock at a weighted average price of $1.22 per share, with individual trade prices ranging from $1.22 to $1.23. The filing explains that these shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plan, and that this was a mandated "sell to cover" transaction rather than a discretionary sale. Following this small sale, the reporting person beneficially owns 217,721 shares of Allogene common stock.
Allogene Therapeutics (ALLO) reported an insider transaction by its Chief Financial Officer. On 10/21/2025, the CFO sold 36,744 shares of common stock at $1.2565 per share. The filing states this was a mandated sell-to-cover to satisfy tax withholding from restricted stock unit vesting and not a discretionary trade.
Following the transaction, the CFO beneficially owned 1,276,796 shares directly. The holdings include shares acquired via the employee stock purchase program: 6,000 shares on March 14, 2025 and 6,000 shares on September 15, 2025.